Sex: F
Vaccine: COVID19
Symptoms: Anterior chamber disorder, Blood test, Eye inflammation, Investigation, Ophthalmological examination
Clinical narrative: Frosted Branch Angiitis in both eyes; intraocular cellular infiltration in anterior chamber; blurred vision; vitreous opacity; vaccine-induced ocular inflammation; long post-COVID vaccination syndrome; Exhibiting fever; This is a spontaneous report received from a Physician.  A 51-year-old female patient received BNT162b2 (BNT162B2), as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "COVID-19" (unspecified if ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, MANUFACTURER UNKNOWN), for COVID-19 immunization. The following information was reported: RETINAL VASCULITIS (medically significant), outcome "not recovered", described as "Frosted Branch Angiitis in both eyes"; ANTERIOR CHAMBER DISORDER (medically significant), outcome "not recovered", described as "intraocular cellular infiltration in anterior chamber"; VISION BLURRED (medically significant), outcome "not recovered", described as "blurred vision"; VITREOUS OPACITIES (medically significant), outcome "not recovered", described as "vitreous opacity"; EYE INFLAMMATION (medically significant), outcome "not recovered", described as "vaccine-induced ocular inflammation"; POST-ACUTE COVID-19 SYNDROME (medically significant), outcome "not recovered", described as "long post-COVID vaccination syndrome"; PYREXIA (non-serious), outcome "not recovered", described as "Exhibiting fever". The patient underwent the following laboratory tests and procedures: Blood test: Unknown results; systemic workups: Unknown results; Ophthalmological examination: intraocular cellular infiltration, notes: in anterior chamber, vitreous opacity, and frosted branch angiitis in both eyes. Therapeutic measures were taken as a result of retinal vasculitis, anterior chamber disorder, vision blurred, vitreous opacities, eye inflammation, post-acute covid-19 syndrome, pyrexia. Clinical Course: Long Vax in the Eye: Long Post-COVID Vaccination Syndrome Presenting with Frosted Branch Angiitis. This research investigated the clinical trajectories of ocular disorders in a 51-year-old female who received a second dose of the BNT162b2 (Pfizer-BioNTech) mRNA COVID-19 vaccine. Exhibiting fever and blurred vision within 24 h post-vaccination, with progressive blurry vision over two months, she underwent in-depth ophthalmologic examinations, revealing intraocular cellular infiltration in anterior chamber, vitreous opacity, and frosted branch angiitis in both eyes. Comprehensive evaluations, including systemic workups as well as ocular and blood specimen analyses, excluded autoimmune and infectious etiologies, consolidating the diagnosis of vaccine-induced ocular inflammation. Despite adherence to prevailing therapeutic protocols, her condition showed no significant improvement over 18 months, pointing to a possible long post-COVID vaccination syndrome. Corticosteroids were effective as a treatment, yet it is crucial to note that full recovery was not achieved in half of the cases, pointing to potential long-lasting effects of these vaccines.  No follow-up attempts are possible. Batch/lot number is not provided, and it cannot be obtained.; Sender's Comments: The reported events can probably be causally related to suspected vaccine based from temporal relation. Case will be reassess pending new information.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate